{"product_id":"002773sz-business-model-canvas","title":"Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ): Canvas Business Model","description":"\u003cp\u003eDelve into the dynamic world of Chengdu Kanghong Pharmaceutical Group Co., Ltd, a powerhouse in the pharmaceutical industry. This blog post unpacks their innovative Business Model Canvas, highlighting critical partnerships, unique value propositions, and robust revenue streams that set them apart in a competitive market. Discover how this company leverages cutting-edge research and development to meet the evolving needs of healthcare providers and patients alike.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eChengdu Kanghong Pharmaceutical Group Co., Ltd - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eChengdu Kanghong Pharmaceutical Group Co., Ltd significantly relies on a network of strategic partnerships to enhance its operational effectiveness and market reach. The following key partnerships play a crucial role in its business model:\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003ePartnerships with research institutions are vital for Kanghong to remain competitive in the pharmaceutical sector. These collaborations often focus on drug development and clinical trials, which are essential for ensuring that products meet regulatory standards. For instance, Kanghong has partnered with local universities and research centers to innovate in the field of drug formulation and delivery systems.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eResearch Institution\u003c\/th\u003e\n\u003cth\u003eCollaboration Focus\u003c\/th\u003e\n\u003cth\u003eYear Established\u003c\/th\u003e\n\u003cth\u003eFunding Amount (CNY)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChengdu University of Traditional Chinese Medicine\u003c\/td\u003e\n\u003ctd\u003eDrug Development\u003c\/td\u003e\n\u003ctd\u003e2018\u003c\/td\u003e\n\u003ctd\u003e5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSichuan University\u003c\/td\u003e\n\u003ctd\u003eClinical Trials\u003c\/td\u003e\n\u003ctd\u003e2020\u003c\/td\u003e\n\u003ctd\u003e3 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChinese Academy of Sciences\u003c\/td\u003e\n\u003ctd\u003eFormulation Research\u003c\/td\u003e\n\u003ctd\u003e2019\u003c\/td\u003e\n\u003ctd\u003e4 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eGlobal Pharmaceutical Companies\u003c\/h3\u003e\n\u003cp\u003eKanghong has formed alliances with various global pharmaceutical companies to leverage their expertise and resources. These partnerships not only enable access to advanced technologies but also facilitate entry into international markets. In 2022, Kanghong signed a collaboration agreement with a leading global pharma firm to co-develop a novel therapeutic agent.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner Company\u003c\/th\u003e\n\u003cth\u003eCollaboration Type\u003c\/th\u003e\n\u003cth\u003eInitial Investment (USD)\u003c\/th\u003e\n\u003cth\u003eProjected Revenue (2023) (USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer Inc.\u003c\/td\u003e\n\u003ctd\u003eCo-Development\u003c\/td\u003e\n\u003ctd\u003e10 million\u003c\/td\u003e\n\u003ctd\u003e50 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovartis AG\u003c\/td\u003e\n\u003ctd\u003eLicensing Agreement\u003c\/td\u003e\n\u003ctd\u003e8 million\u003c\/td\u003e\n\u003ctd\u003e30 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoche Holding AG\u003c\/td\u003e\n\u003ctd\u003eJoint Venture\u003c\/td\u003e\n\u003ctd\u003e12 million\u003c\/td\u003e\n\u003ctd\u003e40 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eDistribution Networks\u003c\/h3\u003e\n\u003cp\u003eEffective distribution is essential for delivering products to various markets. Kanghong has established partnerships with logistics firms and distributors to ensure its pharmaceutical products reach healthcare providers efficiently. Their distribution network covers over 30 provinces in China, supported by a robust logistics framework.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eDistribution Partner\u003c\/th\u003e\n\u003cth\u003eCoverage Area\u003c\/th\u003e\n\u003cth\u003eYear of Partnership\u003c\/th\u003e\n\u003cth\u003eAnnual Revenue Contribution (CNY)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZhengzhou Huachang Logistics\u003c\/td\u003e\n\u003ctd\u003eCentral China\u003c\/td\u003e\n\u003ctd\u003e2017\u003c\/td\u003e\n\u003ctd\u003e50 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuangdong Yunda Express\u003c\/td\u003e\n\u003ctd\u003eSouthern China\u003c\/td\u003e\n\u003ctd\u003e2019\u003c\/td\u003e\n\u003ctd\u003e40 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeijing Tongrentang Logistics\u003c\/td\u003e\n\u003ctd\u003eNorth China\u003c\/td\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003ctd\u003e60 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eGovernment Health Departments\u003c\/h3\u003e\n\u003cp\u003eCollaboration with government health departments is crucial for ensuring compliance with regulations and securing funding for public health initiatives. Kanghong actively engages with local and national health authorities to participate in public health campaigns, especially in areas concerning infectious diseases and chronic health management.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eGovernment Department\u003c\/th\u003e\n\u003cth\u003eCollaboration Focus\u003c\/th\u003e\n\u003cth\u003eGrant Amount (CNY)\u003c\/th\u003e\n\u003cth\u003eImpact Assessment Year\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSichuan Provincial Health Commission\u003c\/td\u003e\n\u003ctd\u003ePublic Health Initiatives\u003c\/td\u003e\n\u003ctd\u003e20 million\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNational Health Commission of the PRC\u003c\/td\u003e\n\u003ctd\u003eResearch Funding\u003c\/td\u003e\n\u003ctd\u003e30 million\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFood and Drug Administration of China\u003c\/td\u003e\n\u003ctd\u003eRegulatory Compliance\u003c\/td\u003e\n\u003ctd\u003e15 million\u003c\/td\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThrough these key partnerships, Chengdu Kanghong Pharmaceutical Group Co., Ltd strategically enhances its capabilities, mitigates risks, and drives innovation within the pharmaceutical industry. The careful alignment of resources and expertise from these partners facilitates a robust business model aimed at growth and sustainability.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eChengdu Kanghong Pharmaceutical Group Co., Ltd - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eThe key activities of Chengdu Kanghong Pharmaceutical Group Co., Ltd. play a pivotal role in establishing its business framework and overall success in the pharmaceutical industry.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003cp\u003eChengdu Kanghong invests significantly in research and development (R\u0026amp;D) to innovate and improve its pharmaceutical offerings. In 2022, the company reported a R\u0026amp;D expenditure of approximately \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e, representing around \u003cstrong\u003e15%\u003c\/strong\u003e of its total revenue. The company focuses on developing therapies for critical conditions, including ophthalmic diseases and autoimmune disorders.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing of Pharmaceuticals\u003c\/h3\u003e\n\u003cp\u003eThe manufacturing process is essential for Chengdu Kanghong, which operates multiple production facilities certified by the National Medical Products Administration (NMPA). The company has a manufacturing capacity of over \u003cstrong\u003e1 billion units\u003c\/strong\u003e annually across its various product lines. In 2022, the production output contributed to approximately \u003cstrong\u003e70%\u003c\/strong\u003e of its total sales, with pharmaceuticals generating revenues around \u003cstrong\u003eRMB 8.3 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eQuality Control\u003c\/h3\u003e\n\u003cp\u003eQuality assurance is a critical component of Chengdu Kanghong's manufacturing operations. The company adheres to stringent quality control measures, with a dedicated team of \u003cstrong\u003e200+\u003c\/strong\u003e quality control personnel. The percentage of products meeting quality standards is reported at over \u003cstrong\u003e99.5%\u003c\/strong\u003e. Additionally, in 2022, the company faced \u003cstrong\u003e0.5%\u003c\/strong\u003e of its batches failing quality control checks, which has been consistent over the past three years, showcasing its commitment to quality.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Distribution\u003c\/h3\u003e\n\u003cp\u003eChengdu Kanghong has established a strong marketing strategy, focusing on both domestic and international markets. The company reported a marketing budget of \u003cstrong\u003eRMB 600 million\u003c\/strong\u003e in 2022, which is about \u003cstrong\u003e7.2%\u003c\/strong\u003e of its total revenue. The distribution network comprises over \u003cstrong\u003e3,000\u003c\/strong\u003e pharmacies and hospitals across China, with international partnerships extending to more than \u003cstrong\u003e20 countries\u003c\/strong\u003e. In 2022, overseas sales accounted for approximately \u003cstrong\u003e10%\u003c\/strong\u003e of total revenue, amounting to \u003cstrong\u003eRMB 1.5 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eKey Activity\u003c\/th\u003e\n    \u003cth\u003eDetails\u003c\/th\u003e\n    \u003cth\u003eFinancial Data (2022)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch and Development\u003c\/td\u003e\n    \u003ctd\u003eInvestment in innovative therapies\u003c\/td\u003e\n    \u003ctd\u003eRMB 1.2 billion (15% of revenue)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eManufacturing of Pharmaceuticals\u003c\/td\u003e\n    \u003ctd\u003eProduction across certified facilities\u003c\/td\u003e\n    \u003ctd\u003eRMB 8.3 billion revenue (70% of total sales)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQuality Control\u003c\/td\u003e\n    \u003ctd\u003eStrict adherence to quality standards\u003c\/td\u003e\n    \u003ctd\u003eOver 99.5% product quality compliance\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMarketing and Distribution\u003c\/td\u003e\n    \u003ctd\u003eDomestic and international sales strategy\u003c\/td\u003e\n    \u003ctd\u003eRMB 600 million marketing budget (7.2% of revenue)\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eChengdu Kanghong Pharmaceutical Group Co., Ltd - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003ch3\u003eSkilled Pharmaceutical Professionals\u003c\/h3\u003e\n\u003cp\u003eChengdu Kanghong employs over \u003cstrong\u003e6,000\u003c\/strong\u003e professionals, including \u003cstrong\u003e1,500\u003c\/strong\u003e R\u0026amp;D personnel. The company focuses on ongoing training and development, with an investment of approximately \u003cstrong\u003eRMB 100 million\u003c\/strong\u003e annually towards workforce skills enhancement.\u003c\/p\u003e\n\n\u003ch3\u003ePatented Drug Formulas\u003c\/h3\u003e\n\u003cp\u003eThe company holds over \u003cstrong\u003e200\u003c\/strong\u003e patents, with a significant portion granted in the therapeutic areas of ophthalmology and oncology. In 2022, Kanghong reported revenue from its patented products reaching approximately \u003cstrong\u003eRMB 2.5 billion\u003c\/strong\u003e, accounting for over \u003cstrong\u003e70%\u003c\/strong\u003e of its total revenue.\u003c\/p\u003e\n\n\u003ch3\u003eAdvanced Manufacturing Facilities\u003c\/h3\u003e\n\u003cp\u003eKanghong's manufacturing capabilities are housed in facilities covering an area of \u003cstrong\u003e120,000 square meters\u003c\/strong\u003e, compliant with international standards. The company has made substantial investments, amounting to approximately \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e, to enhance its production capacity. Current production output stands at around \u003cstrong\u003e10 million units\u003c\/strong\u003e per year.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Laboratories\u003c\/h3\u003e\n\u003cp\u003eThe company operates \u003cstrong\u003e5\u003c\/strong\u003e state-of-the-art research laboratories, with a total investment exceeding \u003cstrong\u003eRMB 500 million\u003c\/strong\u003e in research and development. In 2021, Kanghong allocated about \u003cstrong\u003eRMB 600 million\u003c\/strong\u003e, which is approximately \u003cstrong\u003e10%\u003c\/strong\u003e of its annual revenue, towards R\u0026amp;D activities.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Resource\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n        \u003cth\u003eInvestment Amount\u003c\/th\u003e\n        \u003cth\u003eImpact on Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSkilled Pharmaceutical Professionals\u003c\/td\u003e\n        \u003ctd\u003eOver 6,000 employees, 1,500 R\u0026amp;D staff\u003c\/td\u003e\n        \u003ctd\u003eRMB 100 million annually\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePatented Drug Formulas\u003c\/td\u003e\n        \u003ctd\u003e200+ patents, focus on ophthalmology \u0026amp; oncology\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eRMB 2.5 billion (70% of total revenue)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAdvanced Manufacturing Facilities\u003c\/td\u003e\n        \u003ctd\u003e120,000 square meters, 10 million units\/year\u003c\/td\u003e\n        \u003ctd\u003eRMB 1.2 billion\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Laboratories\u003c\/td\u003e\n        \u003ctd\u003e5 research labs, R\u0026amp;D investment of RMB 600 million\u003c\/td\u003e\n        \u003ctd\u003eRMB 500 million\u003c\/td\u003e\n        \u003ctd\u003e10% of annual revenue\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eChengdu Kanghong Pharmaceutical Group Co., Ltd - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003ch3\u003eInnovative drug solutions\u003c\/h3\u003e\n\u003cp\u003eChengdu Kanghong Pharmaceutical Group specializes in innovative drug solutions, particularly in the fields of ophthalmology, orthopedics, and anesthesia. The company has developed over \u003cstrong\u003e20 innovative drugs\u003c\/strong\u003e, including the first of its kind for various therapeutic areas. As of 2022, Kanghong’s product pipeline includes more than \u003cstrong\u003e30 products\u003c\/strong\u003e in various stages of development, reflecting its commitment to addressing unmet medical needs.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-quality manufacturing standards\u003c\/h3\u003e\n\u003cp\u003eThe company adheres to stringent manufacturing standards, ensuring compliance with the \u003cstrong\u003eGood Manufacturing Practice (GMP)\u003c\/strong\u003e regulations. In 2022, Kanghong reported an annual production capacity estimated at \u003cstrong\u003e10 million units\u003c\/strong\u003e per year. Their facilities are equipped with cutting-edge technology to maintain optimal quality control. Kanghong has achieved several international certifications including \u003cstrong\u003eISO 9001\u003c\/strong\u003e for quality management systems.\u003c\/p\u003e\n\n\u003ch3\u003eStrong R\u0026amp;D capabilities\u003c\/h3\u003e\n\u003cp\u003eKanghong invests significantly in research and development, dedicating approximately \u003cstrong\u003e12% of its annual revenue\u003c\/strong\u003e to R\u0026amp;D—amounting to around \u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e (approximately $185 million USD) in 2022. The company employs over \u003cstrong\u003e600 researchers\u003c\/strong\u003e and collaborates with top universities and research institutes, which enhances its R\u0026amp;D capabilities and innovation potential.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive pricing\u003c\/h3\u003e\n\u003cp\u003eKanghong's pricing strategy positions it competitively within the pharmaceutical market. The company aims to offer drugs at a price point \u003cstrong\u003e10%-20% lower\u003c\/strong\u003e than similar products from multinational competitors. In China, Kanghong reported that its flagship products have a market share of approximately \u003cstrong\u003e15%\u003c\/strong\u003e in their respective categories due to this competitive pricing strategy.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eAspect\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eInnovative Drugs Developed\u003c\/td\u003e\n        \u003ctd\u003eOver 20\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTotal Products in Pipeline\u003c\/td\u003e\n        \u003ctd\u003e30+\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProduction Capacity (per year)\u003c\/td\u003e\n        \u003ctd\u003e10 million units\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAnnual R\u0026amp;D Investment\u003c\/td\u003e\n        \u003ctd\u003e¥1.2 billion (approx. $185 million USD)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Investment as Percentage of Revenue\u003c\/td\u003e\n        \u003ctd\u003e12%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eNumber of Researchers\u003c\/td\u003e\n        \u003ctd\u003e600+\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePrice Advantage Over Competitors\u003c\/td\u003e\n        \u003ctd\u003e10%-20% lower\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarket Share in Key Product Categories\u003c\/td\u003e\n        \u003ctd\u003e15%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eChengdu Kanghong Pharmaceutical Group Co., Ltd - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eChengdu Kanghong Pharmaceutical Group Co., Ltd engages in several customer relationship strategies to enhance its market presence and customer engagement. Below is a breakdown of its customer relationship components.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales Force Interactions\u003c\/h3\u003e\n\n\u003cp\u003eThe company employs a dedicated sales force to interact directly with healthcare providers and pharmaceutical distributors. In 2022, Kanghong reported a sales team comprising over \u003cstrong\u003e500\u003c\/strong\u003e professionals, focusing on building relationships and understanding customer needs. This approach allows the company to tailor its product offerings and services directly to client expectations, resulting in a revenue growth of \u003cstrong\u003e18%\u003c\/strong\u003e year-over-year in its primary therapeutic areas.\u003c\/p\u003e\n\n\u003ch3\u003eContinuous Customer Support\u003c\/h3\u003e\n\n\u003cp\u003eKanghong provides robust customer support to ensure client satisfaction. The company operates a support line that received over \u003cstrong\u003e20,000\u003c\/strong\u003e customer inquiries and support requests in 2022, addressing issues ranging from product information to post-sale services. The resolution rate for customer support queries stands at \u003cstrong\u003e95%\u003c\/strong\u003e, reflecting the company's commitment to high-quality service.\u003c\/p\u003e\n\n\u003ch3\u003eEducational Seminars and Workshops\u003c\/h3\u003e\n\n\u003cp\u003eIn an effort to bolster knowledge around its pharmaceutical offerings, Kanghong organizes numerous educational seminars and workshops. In 2022, they conducted \u003cstrong\u003e15\u003c\/strong\u003e major seminars, attended by around \u003cstrong\u003e3,000\u003c\/strong\u003e healthcare professionals. These events focus on the latest research, product information, and industry trends, fostering a relationship of trust and expertise between Kanghong and its customers.\u003c\/p\u003e\n\n\u003ch3\u003eDigital Engagement Platforms\u003c\/h3\u003e\n\n\u003cp\u003eKanghong has invested significantly in digital engagement channels. The company’s website attracted over \u003cstrong\u003e1 million\u003c\/strong\u003e unique visitors in 2022, facilitating online interactions through product inquiries, order placements, and customer feedback. The implementation of a mobile application has further enhanced engagement, with over \u003cstrong\u003e100,000\u003c\/strong\u003e downloads in the first year of launch, enabling customers to access services and information at their convenience.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer Relationship Type\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003cth\u003eMetrics\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Sales Force\u003c\/td\u003e\n\u003ctd\u003eDedicated sales team interacting with clients\u003c\/td\u003e\n\u003ctd\u003e500 sales professionals; 18% revenue growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer Support\u003c\/td\u003e\n\u003ctd\u003eOngoing support for inquiries and issues\u003c\/td\u003e\n\u003ctd\u003e20,000 inquiries; 95% resolution rate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEducational Seminars\u003c\/td\u003e\n\u003ctd\u003eWorkshops for healthcare professionals\u003c\/td\u003e\n\u003ctd\u003e15 seminars; 3,000 attendees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital Engagement\u003c\/td\u003e\n\u003ctd\u003eOnline platforms for product inquiries and feedback\u003c\/td\u003e\n\u003ctd\u003e1 million unique website visitors; 100,000 app downloads\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eChengdu Kanghong Pharmaceutical Group Co., Ltd - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eThe channels utilized by Chengdu Kanghong Pharmaceutical Group Co., Ltd are diverse, allowing the company to effectively communicate and deliver its value proposition to customers. The following outlines the key channels through which the company operates.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales to Hospitals\u003c\/h3\u003e\n\u003cp\u003eChengdu Kanghong has established a strong presence in the hospital sector, directly supplying pharmaceuticals to over \u003cstrong\u003e2,000 hospitals\u003c\/strong\u003e across China. In 2022, direct sales to hospitals accounted for approximately \u003cstrong\u003e60%\u003c\/strong\u003e of the company's total revenue, highlighting the importance of this channel in their distribution strategy.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Wholesalers\u003c\/h3\u003e\n\u003cp\u003eThe company partners with major pharmaceutical wholesalers, which facilitate distribution across a broader market. In the last fiscal year, sales through wholesalers represented about \u003cstrong\u003e25%\u003c\/strong\u003e of total revenue, with significant partnerships including firms such as \u003cstrong\u003eSinopharm Group Co., Ltd\u003c\/strong\u003e and \u003cstrong\u003eChina Resources Pharmaceutical Group Limited\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Pharmacy Platforms\u003c\/h3\u003e\n\u003cp\u003eWith the increasing digitization of the pharmaceutical industry, Chengdu Kanghong has expanded its reach through online pharmacy platforms. In \u003cstrong\u003e2023\u003c\/strong\u003e, sales from e-commerce channels grew by \u003cstrong\u003e35%\u003c\/strong\u003e year-over-year, contributing around \u003cstrong\u003e10%\u003c\/strong\u003e of the total revenue. Collaborations with platforms such as \u003cstrong\u003eJD Health\u003c\/strong\u003e and \u003cstrong\u003eAlibaba Health\u003c\/strong\u003e have been pivotal in this growth.\u003c\/p\u003e\n\n\u003ch3\u003eRegional Distributors\u003c\/h3\u003e\n\u003cp\u003eThe company employs a network of regional distributors to ensure efficient distribution across various provinces. In \u003cstrong\u003e2022\u003c\/strong\u003e, regional distributors contributed approximately \u003cstrong\u003e5%\u003c\/strong\u003e of the company’s revenue. This channel has provided Chengdu Kanghong access to smaller healthcare facilities and local pharmacies, enhancing market penetration.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eChannel\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n        \u003cth\u003eKey Partners\u003c\/th\u003e\n        \u003cth\u003eNumber of Customers\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDirect Sales to Hospitals\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e2,000+\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmaceutical Wholesalers\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eSinopharm, China Resources\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOnline Pharmacy Platforms\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eJD Health, Alibaba Health\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegional Distributors\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eChengdu Kanghong Pharmaceutical Group Co., Ltd - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eChengdu Kanghong Pharmaceutical Group Co., Ltd serves a variety of customer segments within the healthcare sector. Each of these segments has distinct needs and characteristics that the company addresses through its range of pharmaceutical products.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\u003cp\u003eKanghong supplies a broad array of pharmaceuticals, including critical medications for hospitals and clinics. In 2021, Chinese hospitals reported an annual spending of approximately \u003cstrong\u003e¥8.3 trillion\u003c\/strong\u003e ($1.24 trillion) on healthcare services. Kanghong's focus on innovative drug development enables its products to be integral in hospital formularies.\u003c\/p\u003e\n\n\u003ch3\u003eRetail Pharmacies\u003c\/h3\u003e\n\u003cp\u003eThe retail pharmacy sector in China has shown significant growth, with the market expected to reach about \u003cstrong\u003e¥500 billion\u003c\/strong\u003e ($75 billion) by 2023. Kanghong sells its products to thousands of retail pharmacies, providing buyers with a range of branded and generic drugs. As of 2022, Kanghong was among the top 10 pharmaceutical suppliers to retail chains, accounting for about \u003cstrong\u003e3%\u003c\/strong\u003e of the market share.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Professionals\u003c\/h3\u003e\n\u003cp\u003eHealthcare professionals play a critical role in the distribution and recommendation of Kanghong’s products. The company engages with over \u003cstrong\u003e100,000\u003c\/strong\u003e healthcare professionals annually through outreach initiatives. In its 2022 annual report, Kanghong reported that collaboration with healthcare professionals increased its product endorsement by approximately \u003cstrong\u003e25%\u003c\/strong\u003e, directly impacting sales growth.\u003c\/p\u003e\n\n\u003ch3\u003ePatients Requiring Prescription Drugs\u003c\/h3\u003e\n\u003cp\u003ePatients are a fundamental customer segment for Kanghong, which develops drugs primarily targeting chronic and acute conditions. As of 2023, about \u003cstrong\u003e58%\u003c\/strong\u003e of prescriptions in China are for chronic diseases, emphasizing the importance of Kanghong's offerings. In 2022, the company reported a patient reach of over \u003cstrong\u003e20 million\u003c\/strong\u003e through its various prescription drugs.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Segment\u003c\/th\u003e\n    \u003cth\u003eMarket Size (2023)\u003c\/th\u003e\n    \u003cth\u003eMarket Share\u003c\/th\u003e\n    \u003cth\u003eAnnual Spending\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n    \u003ctd\u003e¥8.3 trillion ($1.24 trillion)\u003c\/td\u003e\n    \u003ctd\u003eNot specified\u003c\/td\u003e\n    \u003ctd\u003eSignificant contributor to total healthcare spending\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRetail Pharmacies\u003c\/td\u003e\n    \u003ctd\u003e¥500 billion ($75 billion)\u003c\/td\u003e\n    \u003ctd\u003e3%\u003c\/td\u003e\n    \u003ctd\u003eGrowing annual sales\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHealthcare Professionals\u003c\/td\u003e\n    \u003ctd\u003eEngagement with \u003cstrong\u003e100,000\u003c\/strong\u003e professionals\u003c\/td\u003e\n    \u003ctd\u003e25% increase in product endorsement\u003c\/td\u003e\n    \u003ctd\u003eInfluences overall sales growth\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePatients Requiring Prescription Drugs\u003c\/td\u003e\n    \u003ctd\u003eReach of \u003cstrong\u003e20 million\u003c\/strong\u003e patients\u003c\/td\u003e\n    \u003ctd\u003e58% of prescriptions for chronic diseases\u003c\/td\u003e\n    \u003ctd\u003eIntegral to revenue generation\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eChengdu Kanghong Pharmaceutical Group Co., Ltd - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003eThe cost structure of Chengdu Kanghong Pharmaceutical Group Co., Ltd encompasses various expenses necessary for its operations. This includes both fixed and variable costs associated with research and development, manufacturing, marketing, and regulatory compliance.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003cp\u003eChengdu Kanghong places a significant emphasis on research and development (R\u0026amp;D). In their 2022 annual report, R\u0026amp;D expenses amounted to approximately \u003cstrong\u003eRMB 674 million\u003c\/strong\u003e, reflecting a commitment to innovation and product development. This accounts for about \u003cstrong\u003e11.4%\u003c\/strong\u003e of the company's total revenue.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Costs\u003c\/h3\u003e\n\u003cp\u003eManufacturing costs for Chengdu Kanghong primarily include the costs of raw materials, labor, and overhead associated with its production facilities. In 2022, the total manufacturing costs were reported at \u003cstrong\u003eRMB 1.5 billion\u003c\/strong\u003e. The breakdown of these costs includes:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eRaw materials: \u003cstrong\u003eRMB 600 million\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eLabor: \u003cstrong\u003eRMB 400 million\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eDepreciation and overhead: \u003cstrong\u003eRMB 500 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eMarketing and Distribution Costs\u003c\/h3\u003e\n\u003cp\u003eFor the fiscal year 2022, marketing and distribution costs for Chengdu Kanghong amounted to \u003cstrong\u003eRMB 320 million\u003c\/strong\u003e. This investment in marketing represents around \u003cstrong\u003e5.3%\u003c\/strong\u003e of total revenue and includes expenditures on advertising campaigns, promotional activities, and logistics costs to ensure effective distribution of products.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance Fees\u003c\/h3\u003e\n\u003cp\u003eChengdu Kanghong incurs regulatory compliance fees as part of its operational costs, essential for maintaining adherence to pharmaceutical regulations. In 2022, regulatory compliance fees were reported at \u003cstrong\u003eRMB 50 million\u003c\/strong\u003e, which covers the costs associated with quality assurance, certification, and ongoing compliance with health authorities.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth\u003eCost Type\u003c\/th\u003e\n      \u003cth\u003eAmount (RMB)\u003c\/th\u003e\n      \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n  \u003c\/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e674 million\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e11.4%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eManufacturing Costs\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e1.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003e-\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eRaw Materials\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e600 million\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003e-\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eLabor\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e400 million\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003e-\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eDepreciation and Overhead\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e500 million\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003e-\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eMarketing and Distribution Costs\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e320 million\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e5.3%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eRegulatory Compliance Fees\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e50 million\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003e-\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eChengdu Kanghong Pharmaceutical Group Co., Ltd - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003eChengdu Kanghong Pharmaceutical Group Co., Ltd operates through multiple revenue streams that significantly contribute to its financial health. As of the latest financial reports, the company has diversified its revenue base effectively.\u003c\/p\u003e\n\n\u003ch3\u003ePrescription Drug Sales\u003c\/h3\u003e\n\u003cp\u003ePrescription drug sales constitute a substantial portion of Chengdu Kanghong's revenue. The company reported \u003cstrong\u003e¥5.3 billion\u003c\/strong\u003e in prescription drug sales for the fiscal year 2022. Their leading products include drugs for ophthalmology and orthopedic indications, which have seen a year-on-year growth of \u003cstrong\u003e15%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOver-the-Counter Product Sales\u003c\/h3\u003e\n\u003cp\u003eThe revenue generated from over-the-counter (OTC) products has marked significant growth. In 2022, Chengdu Kanghong's OTC sales amounted to \u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e, representing an increase of \u003cstrong\u003e10%\u003c\/strong\u003e compared to the previous year. The company focuses on a range of health supplements and pain relief medications that cater to broader consumer markets.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing Agreements\u003c\/h3\u003e\n\u003cp\u003eLicensing agreements form another critical revenue stream for Chengdu Kanghong. The company has entered various partnerships for the development and commercialization of its products. In the latest earnings report, licensing revenue was reported at \u003cstrong\u003e¥800 million\u003c\/strong\u003e, which includes royalties from international markets. This segment has shown an annual growth rate of \u003cstrong\u003e20%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eGovernment and Institutional Contracts\u003c\/h3\u003e\n\u003cp\u003eChengdu Kanghong also generates revenue through contracts with government and institutional buyers. The company secured contracts worth \u003cstrong\u003e¥2.5 billion\u003c\/strong\u003e in 2022, primarily for the supply of essential drugs to public health facilities. This segment is critical given the consistent demand for affordable healthcare solutions.\u003c\/p\u003e\n\n\u003ch3\u003eRevenue Breakdown\u003c\/h3\u003e\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eRevenue Stream\u003c\/th\u003e\n        \u003cth\u003e2022 Revenue (¥ Billion)\u003c\/th\u003e\n        \u003cth\u003eYear-on-Year Growth (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePrescription Drug Sales\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e5.3\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOver-the-Counter Product Sales\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1.2\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLicensing Agreements\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e0.8\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eGovernment and Institutional Contracts\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e2.5\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe diverse revenue streams of Chengdu Kanghong Pharmaceutical Group provide stability and opportunities for future growth, reflecting the company’s commitment to expanding its market presence and enhancing its product offerings.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45662170480789,"sku":"002773sz-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/002773sz-business-model-canvas.png?v=1739111452","url":"https:\/\/dcf-model.com\/pt\/products\/002773sz-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}